中药穴位贴敷疗法联合静脉补液治疗肝胃不和型妊娠恶阻

〔摘 要〕 目的：探讨中药穴位贴敷联合静脉补液治疗肝胃不和型妊娠恶阻患者疗效及对焦虑自评量表（SAS）、 抑郁自评量表（SDS）评分的影响。方法：选取泉州市中医院 2019 年 1 月至 2021 年 12 月期间收治的 80 例肝胃不和 型妊娠恶阻患者，随机分为两组，其中 40 例患者接受静脉补液治疗为对照组，40 例患者接受中药贴敷联合静脉补液 治疗为观察组。比较两组患者的疗效和复发情况，两组患者进食量、妊娠恶心呕吐专用量表（PUQE）、SAS、SDS 评分、 中医临床症状积分和尿酮体水平。结果：观察组患者治疗总有效率为 95.00 %，高于对照组的 80.00 %，差异具有统 计学意义（P ＜ 0.05）；观察组患者的复发率为 5.00 %，明显低于对照组的 22.50 %，差异具有统计学意义（P ＜ 0.05）； 治疗 2 d 后，观察组患者进食量明显大于对照组，差异具有统计学意义（P ＜ 0.05）；治疗后两组患者的尿酮体、 临床症状积分均较治疗前降低，且治疗后观察组患者的尿酮体、临床症状积分均低于对照组，差异具有统计学意义 （P ＜ 0.05）；治疗后两组患者的 PUQE、SAS、SDS 评分均较治疗前降低，且治疗后观察组患者的 PUQE、SAS、 SDS 评分均低于对照组，差异具有统计学意义（P ＜ 0.05）。结论：中药穴位贴敷联合静脉补液治疗可有效减轻肝胃 不和型妊娠恶阻的临床症状，缓解患者焦虑和抑郁状态。     

穴位敏化柔性辅助检测传感器的研发＊

目的 为了进一步提高穴位敏化研究效率，促进穴位敏化传感器的发展以及穴位敏化可穿戴设备的研发。方法 根据穴位敏化理论设计传感器功能，对照分析多种材料，使用柔性印刷电路板（flexible printed circuit，FPC）作为支撑体，结合体积小、功耗低的热敏电阻，设计能固定于体表穴位、可动态传输多种物理量的穴位敏化辅助检测传感器（Acupoint sensitization auxiliary detection sensor，ASADS）。结果 提出有别于传统传感器的穴位敏化传感器新构想；开发出了基于FPC的，可同时完成测量电阻值及温度值并输出低频脉冲信号模拟针刺的柔性可穿戴传感器。结论 穴位敏化辅助检测传感器具有可穿戴、功能集成、动态监测等优点。它将有利于简化穴位敏化研究采集步骤、缩减操作时间。柔性印刷电路板可作为目前的传感器现实需求的过渡。未来，多功能集成、动态监测、可穿戴与织物整合、柔性功能材料是穴位敏化传感器的发展方向。     

针灸治疗药物依赖者稽延期抑郁症的选穴规律研究

目的　分析针灸治疗药物依赖者稽延期抑郁症的用穴规律。方法　通过检索中英文数据库收集有关针灸治疗药物依赖者稽延期抑郁症的临床文献，建立其处方数据库，采用SPSS 22.0对其进行描述性分析和聚类分析，采用SPSS Modeler 18.0对其进行关联规则分析，探究针灸治疗药物依赖者稽延期抑郁症的腧穴运用特点及其规律。结果　对纳入的28篇文献进行分析，结果显示，针灸治疗药物依赖者稽延期抑郁症最常用的腧穴配伍存在固定搭配，经穴置信度最高的关联群为内关-三阴交-神门和足三里-三阴交-神门；通过聚类分析可得到2个聚类群。结论　通过数据挖掘技术发现针灸治疗药物依赖者稽延期抑郁症存在一定规律，内关、足三里、神门、三阴交为针灸治疗药物依赖者稽延期抑郁症的主要腧穴。     

Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study

We studied the safety and efficacy of 0 U, 50 U, 100 U, 150 U (five sites), 86 Usub and 100 Usub (three sites) botulinum toxin type A (BoNTA; BOTOX); Allergan, Inc., Irvine, CA, USA) for the prophylaxis of chronic tension-type headache (CTTH). Three hundred patients (62.3% female; mean age 42.6 years) enrolled. For the primary endpoint, the mean change from baseline in the number of TTH-free days per month, there was no statistically significant difference between placebo and four BoNTA groups, but a significant difference favouring placebo vs. BoNTA 150 was observed (4.5 vs. 2.8 tension headache-free days/month; P = 0.007). All treatment groups improved at day 60. Although efficacy was not demonstrated for the primary endpoint, at day 90, more patients in three BoNTA groups had >or=50% decrease in tension headache days than did placebo (P 相似文献   

Early treatment in migraine: how strong is the current evidence?

Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia 2008; 28:28–35. London. ISSN 0333-1024
Over the last 10 years, triptans (serotonin 5-HT_1B/1D receptor agonists) have proved to be efficacious in treating migraine pain. However, recent evidence suggests that patients are still not receiving optimal pain management, particularly in clinical trials, where triptan treatment is generally not initiated until pain has reached moderate intensity. Pathophysiological evidence indicates that if treatment is initiated at an early stage, while pain is still mild and before the onset of central sensitization, outcomes for patients may be improved. In addition, a small number of clinical trials have been reported in which triptans were taken early (within 1 h of pain onset) or while pain was still mild; although constraints of trial design and data analysis limit definite conclusions, overall the results suggest that this early/mild approach results in more rapid and sustained pain relief. New studies are therefore needed to clarify the clinical benefits of early treatment, whilst taking into account potential risks, such as medication overuse. Ultimately, migraine treatment strategies require optimization in order to meet patient expectations and to reduce the current burden of migraine-associated disability.     

Pharmacokinetics,pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019

We have recently reported that glioblastoma (GB)‐initiating cells (GIC) with low expression and/or mutation of TP53 and high expression of PI3K (“responder” genetic profile) can be effectively and safely radiosensitized by the ATM inhibitor KU60019. We report here on drug's diffusion and elimination from the animal body and brain, its effects on orthotopic GB and efficacy toward pediatric GIC. Healthy mice were infused by convection enhanced delivery (CED) with KU60019 and the drug kinetics followed by high performance liquid chromatography–mass spectrometry. Already at the end of CED, KU60019 had diffused from the injection site to the ipsilateral and, to a lower extent, controlateral hemisphere. After 24 hr, no drug could be detected all over the brain or in other organs, indicating rapid draining and excretion. After intraperitoneal injection, traces only of KU60019 could be detected in the brain, indicating inability to cross the brain–blood barrier. Consistent with the induction of cell cycle progression previously observed in vitro, KU60019 stimulated proliferation of orthotopic GB cells with the highest effect observed 96 hr after drug delivery. Adult GIC with high expression of TP53 and low expression of PI3K could be radiosensitized by KU60019, although less promptly than GIC bearing the “responder” profile. Consistent with the kinetics of proliferation induction, the highest radiosensitizing effect was observed 96 hr after delivery of KU60019 to GIC. Pediatric GIC could be similarly radiosensitized after exposure to KU60019. The results indicate that ATM inhibition may allow to radiosensitize a wide range of adult and pediatric high‐grade gliomas.     

穴位贴敷为主治疗乳腺增生病疗效观察

目的观察穴位贴敷、走罐配合光电离子治疗仪治疗乳腺增生病的临床疗效。方法将60例乳腺增生病患者随机分为治疗组和对照组,每组30例。治疗组采用穴位贴敷、走罐配合光电离子治疗仪治疗,对照组采用口服三苯氧胺、乳癖散结片治疗。治疗2个月后,观察两组治疗前后乳房疼痛及肿块积分,比较两组临床疗效。结果两组治疗后乳房疼痛及肿块积分与同组治疗前比较,差异均具有统计学意义(P0.05)。治疗组治疗后乳房疼痛及肿块积分与对照组比较,差异均无统计学意义(P0.05)。治疗组总有效率为96.7%,对照组为86.7%,两组比较差异具有统计学意义(P0.05)。结论穴位贴敷、走罐配合光电离子治疗仪是一种治疗乳腺增生病的有效方法,能消除或减轻乳房疼痛,改善或减小乳腺增生肿块及分布。